Expanding Genome Accessibility Beyond SP-Cas9 Limitations Using AI-Enhanced Nuclease Platforms to Target Non-NGG PAM Sequences

• Addressing SP-Cas9 PAM sequence limitations that restrict targetability to only five percent of the human genome for conventional gene editing applications
• Leveraging AI-based technology to optimize diverse nuclease platforms recognizing alternative PAM sequences, reducing off-target activity and improving delivery compatibility for therapeutic applications
• Implementing AI-driven nuclease engineering to expand platform robustness and efficiency, enabling faster development of next-generation CRISPR tools including prime editors and base editors for therapeutic purposes

Speakers:

Noa Wertheimer

Director, Scientific Strategy

EmendoBio